D'Haens GR - Search Results

1

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.

Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.

2

Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease.

D'Haens GR, Gasparaitis AE, Hanauer SB. D'Haens GR, et al. Gut. 1995 May;36(5):715-7. doi: 10.1136/gut.36.5.715. Gut. 1995. PMID: 7797122 Free PMC article.

3

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Baert FJ, et al. Gastroenterology. 1999 Jan;116(1):22-8. doi: 10.1016/s0016-5085(99)70224-6. Gastroenterology. 1999. PMID: 9869598 Clinical Trial.

4

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. D'haens G, et al. Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3. Gastroenterology. 1999. PMID: 10220494 Clinical Trial.

5

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.

6

Infliximab (Remicade), a new biological treatment for Crohn's disease.

D'Haens GR. D'Haens GR. Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):519-20. Ital J Gastroenterol Hepatol. 1999. PMID: 10575573 Review.

7

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.

Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J. Louis E, et al. Scand J Gastroenterol. 2002 Jul;37(7):818-24. Scand J Gastroenterol. 2002. PMID: 12190096 Free article.

8

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.

Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.

9

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Baert F, et al. N Engl J Med. 2003 Feb 13;348(7):601-8. doi: 10.1056/NEJMoa020888. N Engl J Med. 2003. PMID: 12584368 Free article. Clinical Trial.

10

Infliximab as disease-modifying therapy.

D'Haens GR. D'Haens GR. Eur J Gastroenterol Hepatol. 2003 Mar;15(3):233-7. doi: 10.1097/00042737-200303000-00004. Eur J Gastroenterol Hepatol. 2003. PMID: 12610316 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

579 results

Search Page